Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Betty Y Zhang, Ashley R Wilson-Smith, Elizabeth A Connolly, Madeleine C Strach, Nathan Ussher, Tristan Yan, Vivek A Bhadri
BACKGROUND: Extrapleural pneumonectomy (EPP) is a complex surgical procedure involving en-bloc resection of the parietal and visceral pleura, lung, pericardium, and ipsilateral diaphragm. Small case series of pleural-based sarcoma of predominantly pediatric patients suggest EPP may be a life-prolonging surgical option. We aimed to describe the characteristics and outcomes of adults who underwent EPP at a specialized sarcoma center. METHODS: Clinicopathologic variables, surgical details, and follow-up information were extracted for patients undergoing EPP for pleural-based sarcoma between August 2017 and December 2020...
April 2024: Cancer reports
#2
Jinfeng Sun, Xiuli Gu, Liangjun Wang
INTRODUCTION: This systematic review and meta-analysis aimed to examine the risk of second primary cancers (SPCs) among retinoblastoma (Rb) patients, both hereditary and nonhereditary. Previous studies have reported on the long-term risk of SPCs in these patient populations, but a comprehensive synthesis of the existing evidence is lacking. METHODS: A systematic search was conducted in PubMed, EMBASE, and Cochrane Library from inception to 12 March 2023, supplemented by manual screening...
2024: Frontiers in Oncology
#3
REVIEW
Elena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, Marta Barisella, Giuseppe Bianchi, Domenico Campanacci, Marco Fiore, Marco Gambarotti, Massimiliano Gennaro, Carlo Morosi, Federico Navarria, Emanuela Palmerini, Claudia Sangalli, Marta Sbaraglia, Annalisa Trama, Sebastian Asaftei, Giuseppe Badalamenti, Rossella Bertulli, Alexia Francesca Bertuzzi, Roberto Biagini, Angela Bonadonna, Antonella Brunello, Dario Callegaro, Ferdinando Cananzi, Marco Cianchetti, Paola Collini, Danila Comandini, Annalisa Curcio, Lorenzo D'Ambrosio, Tommaso De Pas, Angelo Paolo Dei Tos, Virginia Ferraresi, Andrea Ferrari, Alessandro Franchi, Anna Maria Frezza, Elena Fumagalli, Matteo Ghilli, Daniela Greto, Giovanni Grignani, Michele Guida, Toni Ibrahim, Marco Krengli, Roberto Luksch, Andrea Marrari, Marinella Mastore, Alessandra Merlini, Giuseppe Maria Milano, Piera Navarria, Maria Abbondanza Pantaleo, Antonina Parafioriti, Ilaria Pellegrini, Elisabetta Pennacchioli, Marco Rastrelli, Elisabetta Setola, Salvatore Tafuto, Salvatore Turano, Sergio Valeri, Bruno Vincenzi, Viviana Vitolo, Andrei Ivanescu, Fiammetta Paloschi, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice guidelines for sarcoma treatment are applicable to AS, its unique aggressiveness and diverse tumor presentations necessitate dedicated and detailed clinical recommendations, which are currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), and neoadjuvant/adjuvant chemotherapy vary significantly in localized disease, depending on each different site of onset...
March 30, 2024: Cancer Treatment Reviews
#4
JOURNAL ARTICLE
Diogo Catelas, Duarte Sousa, Ana Patrícia Rodrigues, Pedro Cardoso
Malignant peripheral nerve sheath tumour (MPNST) is an aggressive soft tissue sarcoma with a poor prognosis, affecting most commonly the extremities. The lungs constitute the most frequent location for distant metastases. Half of all MPNSTs arise in patients with neurofibromatosis type 1, while approximately 10% are radiation induced and the rest are sporadic.The authors present a pregnant woman in her 40s with a sporadic MPNST of the lower limb and with lung metastases at diagnosis. Treatment consisted of interilioabdominal amputation, followed by adjuvant chemotherapy...
April 3, 2024: BMJ Case Reports
#5
JOURNAL ARTICLE
Geetha Narayanan, Lakshmi H Kamala, Sreejith G Nair, Prakash N Purushothaman, Aswin Kumar, Jayasree Kattoor
BACKGROUND: Ewing's sarcoma (EWS) is an aggressive small round cell tumor, affecting bone and soft tissues and is mostly seen in childhood and second decade of life. EWS accounts for 10-12% of bone tumors in more than 15 years age group and is even rarer after 40 years of age. MATERIALS AND METHODS: This retrospective analysis was conducted among patients aged more than 15 years with histologically proven EWS. RESULTS: Among 240 cases of EWS treated at our center during 2001-2010, 130 (54%) were more than 15 years of age...
January 1, 2024: Journal of Cancer Research and Therapeutics
#6
JOURNAL ARTICLE
Sylvia M Cruz, Khurshid R Iranpur, Sean J Judge, Erik Ames, Ian R Sturgill, Lauren E Farley, Morgan A Darrow, Jiwon Sarah Crowley, Arta M Monjazeb, William J Murphy, Robert J Canter
The cancer stem cell (CSC) hypothesis postulates that heterogeneous human cancers harbor a population of stem-like cells which are resistant to cytotoxic therapies, thus providing a reservoir of relapse following conventional therapies like chemotherapy and radiation (RT). CSCs have been observed in multiple human cancers, and their presence has been correlated with worse clinical outcomes. Here, we sought to evaluate the impact of drug dosing of the multi-tyrosine kinase inhibitor, sorafenib, on CSC and non-CSCs in soft tissue sarcoma (STS) models, hypothesizing differential effects of sorafenib based on dose and target cell population...
March 15, 2024: International Journal of Molecular Sciences
#7
JOURNAL ARTICLE
Brianna Conte, Dana L Casey, Kathryn R Tringale, Michael P LaQuaglia, J Ted Gerstle, Leonard Wexler, Michael V Ortiz, Suzanne L Wolden
PURPOSE: To evaluate local failure (LF) and toxicity after intraoperative radiation therapy (IORT) in pediatric solid tumors (ST). METHODS: A single-institution retrospective study of 96 pediatric patients (108 applications) with ST treated from 1995 to 2022 with IORT. LF was calculated via cumulative incidence function and overall survival (OS) by Kaplan-Meier method, both from the day of surgery. RESULTS: Median age at time of IORT was 8 years (range: 0...
March 22, 2024: Pediatric Blood & Cancer
#8
REVIEW
Srinithya R Gillipelli, Luca Pio, Paul D Losty, Abdelhafeez H Abdelhafeez
BACKGROUND AND AIMS: As survival rates in childhood cancer progress significantly, health outcomes in adulthood are pivotal to quality of life (QoL). Female patients undergoing chemotherapy and radiation for childhood cancer may experience adverse effects such as gonadotoxicity-related ovarian insufficiency. Ovarian tissue cryopreservation (OTC) is well studied in adults, but has only recently started to be explored in an effort to preserve fertility in young patients with childhood cancer...
March 1, 2024: Journal of Pediatric Surgery
#9
REVIEW
B Ashleigh Guadagnolo, Elizabeth H Baldini
This critical review aims to summarize the relevant published data regarding hypofractionation regimens for preoperative radiation therapy (RT) prior to surgery for soft tissue sarcoma (STS) of the extremity or superficial trunk. We identified peer-reviewed publications using a PubMed search on the MeSH headings of "soft tissue sarcoma" AND "hypofractionated radiation therapy." To obtain complication data on similar anatomical radiotherapeutic scenarios we also searched "hypofractionated radiation therapy" AND "melanoma" as well as "hypofractionated radiation therapy" AND "breast cancer...
April 2024: Seminars in Radiation Oncology
#10
REVIEW
Alessandra Borghi, Alessandro Gronchi
Extremity and truncal soft tissue sarcomas are a heterogeneous group of rare cancers that arise from mesenchymal tissues. Hence, the adoption of tailored risk assessment and prognostication tools plays a crucial role in optimizing the decision-making for which of the many possible treatment strategies to select. Management of these tumors requires a multidisciplinary strategy, which has seen significant development in recent decades. Surgery has emerged as the primary treatment approach, with the main goal of achieving microscopic negative tumor margins...
April 2024: Seminars in Radiation Oncology
#11
REVIEW
Yixian Wang, Chenhang Wang, Meng Xia, Zeru Tian, Joseph Zhou, Julian Meyer Berger, Xiang Zhang, Han Xiao
Bone cancer is common and severe. Both primary (e.g., osteosarcoma, Ewing sarcoma) and secondary (e.g., metastatic) bone cancers lead to significant health problems and death. Currently, treatments such as chemotherapy, hormone therapy, and radiation therapy are used to treat bone cancer, but they often only shrink or slow tumor growth and don't eliminate cancer completely. The bone microenvironment contributes unique signals that influence cancer growth, immunogenicity, and metastasis. Traditional cancer therapies have limited effectiveness due to off-target effects and poor distribution on bones...
March 5, 2024: Molecular Therapy
#12
JOURNAL ARTICLE
Ryoko Rikitake, Yu Mizushima, Seiichi Yoshimoto, Takahiro Higashi, Tomoyuki Satake, Chigusa Morizane, Akira Kawai
BACKGROUND: Head and neck sarcomas are especially rare in Asia, leading to limited clinical evidence. This study aimed to investigate the incidence, clinical features, treatment status, and outcome of these sarcomas using data from the National Cancer Registry in Japan. METHODS: All head and neck sarcomas diagnosed between 2016 and 2019 and recorded in the National Cancer Registry were analyzed. Data on sex, age, primary site, histological type, stage, treatment modality, and prognostic information were collected...
February 27, 2024: International Journal of Clinical Oncology
#13
JOURNAL ARTICLE
Xiao-Yu Jing, Cheng-Qi Shen, Guo-Qian He, Rong-Rong Xu, Ju Gao, Xia Guo
INTRODUCTION: Desmoplastic small round cell tumor (DSRCT) is a highly aggressive primitive sarcoma with a 5-year survival rate estimated at only 15% to 30%. Although few curative treatment options exist, patients are most often treated with a combination of aggressive chemotherapy, radiation, and surgery. Targeted therapy inhibitors of platelet-derived growth factor A, insulin-like growth factor receptor 1, and vascular endothelial growth factor receptor-2, which are almost uniformly overexpressed in DSRCT, have largely failed in clinical trials...
February 22, 2024: Journal of Pediatric Hematology/oncology
#14
JOURNAL ARTICLE
Nina A Mayr, Majid Mohiuddin, James W Snider, Hualin Zhang, Robert J Griffin, Beatriz E Amendola, Daniel S Hippe, Naipy C Perez, Xiaodong Wu, Simon S Lo, William F Regine, Charles B Simone
PURPOSE: Spatially fractionated radiation therapy (SFRT) is increasingly used for bulky advanced tumors, but specifics of clinical SFRT practice remain elusive. This study aimed to determine practice patterns of GRID and Lattice radiation therapy (LRT)-based SFRT. METHODS AND MATERIALS: A survey was designed to identify radiation oncologists' practice patterns of patient selection for SFRT, dosing/planning, dosimetric parameter use, SFRT platforms/techniques, combinations of SFRT with conventional external beam radiation therapy (cERT) and multimodality therapies, and physicists' technical implementation, delivery, and quality procedures...
February 2024: Advances in Radiation Oncology
#15
JOURNAL ARTICLE
Daniel J Benedetti, Lindsay A Renfro, Ian Tfirn, Najat C Daw, John A Kalapurakal, Peter F Ehrlich, Geetika Khanna, Elizabeth Perlman, Anne Warwick, Kenneth W Gow, Arnold C Paulino, Nita L Seibel, Paul Grundy, Conrad V Fernandez, James I Geller, Elizabeth A Mullen, Jeffrey S Dome
BACKGROUND: On the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5-year event-free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children's Oncology Group study AREN0321 of risk-adapted therapy, RT was omitted for stage I disease if lymph nodes were sampled, and carboplatin was added for stage IV disease (regimen UH-1)...
February 23, 2024: Cancer
#16
JOURNAL ARTICLE
Raymond S Traweek, Heather G Lyu, Russell G Witt, Rebecca A Snyder, Elise F Nassif, David D Krijgh, Jeffrey M Smith, Gordon S Tilney, Chun Feng, Yi-Ju Chiang, Keila E Torres, Margaret J Roubaud, Christopher P Scally, Kelly K Hunt, Emily Z Keung, Alexander F Mericli, Christina L Roland
BACKGROUND: Although social vulnerability has been associated with worse postoperative and oncologic outcomes in other cancer types, these effects have not been characterized in patients with soft tissue sarcoma. This study evaluated the association of social vulnerability and oncologic outcomes. METHODS: The authors conducted a single-institution cohort study of adult patients with primary and locally recurrent extremity or truncal soft tissue sarcoma undergoing resection between January 2016 and December 2021...
February 23, 2024: Annals of Surgical Oncology
#17
Vaishnavi M Thakre, Vrushali Athawale, Tejaswini Fating
Ewing sarcoma (ES) is a highly fatal bone and soft tissue cancer that predominantly impacts adolescents and children. Primary ES can occasionally manifest as a tumour on the chest wall. Treatment typically consists of radiation, local surgery, and polychemotherapy, all of which have acute and chronic side effects that can detrimentally affect survivors' quality of life (QOL). In this case study, we discussed the case of a 19-year-old female who came with chief complaints of chest pain, swelling on the right side of her neck, difficulty breathing, and pain in her right shoulder radiating to her right arm and forearm for one year...
January 2024: Curēus
#18
JOURNAL ARTICLE
Lu Xie, Xin Sun, Jie Xu, Xin Liang, Kuisheng Liu, Kunkun Sun, Rongli Yang, Xiaodong Tang, Wei Guo
BACKGROUND: Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients. METHODS: We retrospectively reviewed data from patients with metastatic or unresectable epithelioid sarcoma at the Peking University People's Hospital treated with irinotecan (50 mg/m2 /d d1-5 Q3W) in combination with Anlotinib (12 mg Qd, 2 weeks on and 1 week off) from July 2015 to November 2021...
February 3, 2024: BMC Cancer
#19
REVIEW
Shivani Dalal, Khine Swe Shan, Nyein Nyein Thaw Dar, Atif Hussein, Alejandra Ergle
Sarcomas are a group of malignancies of mesenchymal origin with a plethora of subtypes. Given the sheer heterogeneity of various subtypes and the rarity of the disease, the management of sarcomas has been challenging, with poor patient outcomes. Surgery, radiation therapy and chemotherapy have remained the backbone of treatment in patients with sarcoma. The introduction of immunotherapy has revolutionized the treatment of various solid and hematological malignancies. In this review, we discuss the basics of immunotherapy and the immune microenvironment in sarcomas; various modalities of immunotherapy, like immune checkpoint blockade, oncolytic viruses, cancer-targeted antibodies, vaccine therapy; and adoptive cell therapies like CAR T-cell therapy, T-cell therapy, and TCR therapy...
January 19, 2024: International Journal of Molecular Sciences
#20
JOURNAL ARTICLE
Marija Kacar, Margaret B Nagel, Jia Liang, Yimei Li, Michael D Neel, John T Lucas, M Beth McCarville, Teresa Santiago, Alberto S Pappo, Matthew J Krasin
BACKGROUND: Local control for patients with Ewing sarcoma (EWS) who present with large tumors are suboptimal when treated with standard radiation therapy (RT) doses of 54-55.8 Gy. The purpose of this study is to determine local control and toxicity of dose-escalated RT for tumors ≥8 cm (greatest diameter at diagnosis) in pediatric and young adult patients with EWS. METHODS: Eligible patients ≤30 years old with newly diagnosed EWS ≥8 cm treated with definitive conformal or intensity modulated photon, or proton radiation therapy techniques were included...
January 25, 2024: Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
